Agensys and Sea Lane Biotechnologies Sign Commercial License Agreement for Antibodies Generated Using ConCIRT Libraries


Santa Monica and Mountain View, CA, U.S.A., JUNE 2, 2014 - Agensys, Inc. (“Agensys”), a wholly owned subsidiary of Astellas Pharma Inc. (“Astellas”), and Sea Lane Biotechnologies (“Sea Lane”) jointly announced today that Agensys has taken a commercial license to antibodies generated using Sea Lane’s ConCIRT libraries and related technology. Located in the Silicon Valley, Sea Lane is a biotech company with technologies and inventions that include the therapeutic class of entities known as Surrobodies™ and human antibody libraries.
“We are excited by the potential of these unique antibodies to help treat disease,” said David Stover, Ph.D., Executive V.P., Site Head at Agensys.


Under the terms of the agreement, Sea Lane grants Agensys a license to commercialize antibodies generated using its patented ConCIRT libraries, and Agensys will be responsible for preclinical research, clinical development, and marketing of the licensed biotherapeutic products.


"We are very pleased to enter into this agreement with Agensys," commented Lawrence Horowitz, M.D., Chief Executive Officer of Sea Lane. "The progression of our relationship with Agensys shows the potential for innovative technologies such as our ConCIRT libraries and related technologies to facilitate discovery and development of biotherapeutics for large pharmaceutical companies."


About Sea Lane Biotechnologies, LLC
Sea Lane Biotechnologies, LLC is a private biotechnology company focused on innovating biotherapeutic discovery with transformative technologies and platforms that are necessary to meet contemporary pharmaceutical biologic portfolio requirements, including bispecific and drug conjugated agents. Founded in 2005 in the Silicon Valley, the company is dedicated to the discovery and development of biotherapeutic drugs based upon a novel class of proteins called Surrobodies™ and the discovery of world-class antibodies for the treatment of serious human diseases, such as cancer and viral infection. Sea Lane currently has several proprietary product candidates in preclinical development. 


About Agensys, Inc.
Agensys, Inc., an affiliate of Astellas Pharma Inc., is developing a pipeline of fully human monoclonal antibodies (MAbs) to treat cancer. The MAb product pipeline is being generated to Agensys’ diverse portfolio of proprietary, clinically relevant cancer targets.  The company has full capabilities to generate, develop and manufacture antibody products. Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies.



For further information please contact them at


© 2014, Sea Lane Biotechnologies, LLC.  All Rights Reserved.